Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.
Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:
- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms
Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its first-quarter 2025 financial results announcement for May 8, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights.
Investors can access the live webcast through Vericel's Investor Relations website. Call participants can dial (800) 715-9871 domestically or (646) 307-1963 internationally. Presentation slides will be available on the webcast and investor relations section. A replay will remain accessible on the company website until May 8, 2026.
Vericel (NASDAQ:VCEL), a specialized company in advanced therapies for sports medicine and severe burn care markets, has announced its participation in three major upcoming investor conferences in March 2025:
- TD Cowen 45th Annual Health Care Conference - March 5, 2025
- Canaccord Genuity 2025 Musculoskeletal Conference - March 10, 2025
- Leerink Partners 2025 Global Healthcare Conference - March 12, 2025
The company will make presentations at each event, with webcasts available through Vericel's Investor Relations website section at investors.vcel.com.
Vericel (NASDAQ:VCEL) reported strong financial results for Q4 and full-year 2024. The company achieved 20% total revenue growth to $237.2 million for the full year, with MACI revenue up 20% to $197.3 million and Burn Care revenue growing 22% to $39.9 million.
Q4 highlights include total net revenue of $75.4 million, record gross margin of 78%, and net income of $19.8 million. The company reported strong MACI Arthro launch indicators with approximately 250 surgeons trained. Cash position stands at $167 million with no debt.
For 2025, Vericel projects revenue growth of 20-23%, with gross margin expected at 73-74%. The company also updated its mid-term profitability targets, expecting gross margin in the high-70% range and adjusted EBITDA margin in the high-30% range by 2029.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its fourth-quarter and full-year 2024 financial results announcement for February 27, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss financial results and business highlights. The presentation will be accessible through the company's Investor Relations website, with slides available during the call. A replay of the webcast will remain available until February 27, 2026.
Vericel (VCEL) reported strong preliminary 2024 results with total revenue of approximately $237-237.5 million, representing 20% growth. MACI revenue reached $197.2-197.7 million (20% growth), while Burn Care revenue hit $40 million (22% growth).
The fourth quarter showed impressive performance with total revenue of $75.2-75.7 million, including record-breaking MACI implants, surgeons, and biopsies. Gross margin reached approximately 77%, with adjusted EBITDA margin at 39%. The company ended 2024 with $167 million in cash and no debt.
Looking ahead, Vericel projects 20-23% revenue growth for 2025, with gross margin of 73-74% and adjusted EBITDA margin of 25-26%. The company also increased its mid-term profitability targets, expecting gross margin in the high-70% range and adjusted EBITDA margin in the high-30% range by 2029.
Vericel (NASDAQ:VCEL), a leading provider of advanced therapies for sports medicine and severe burn care, has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 a.m. ET (7:30 a.m. PT).
Interested parties can access a webcast of the presentation through the Investor Relations section of Vericel's website at http://investors.vcel.com.
Vericel (NASDAQ:VCEL) reported strong Q3 2024 financial results with total revenue increasing 27% to $57.9 million. The company achieved record quarterly revenues, with MACI net revenue growing 19% to $44.7 million and Burn Care revenue rising 66% to $13.2 million. Gross margin improved to 72%, and adjusted EBITDA increased 84% to $10.0 million. The quarter saw FDA approvals for MACI Arthro and NexoBrid pediatric indication. The company maintained its 2024 revenue guidance of $238-242 million while raising profitability guidance to 72% gross margin and 22% adjusted EBITDA margin.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, announced it will release its third-quarter 2024 financial results on Thursday, November 7, 2024. The company will host a conference call and webcast at 8:30 a.m. (ET) to discuss financial results and business highlights. The event will include presentation slides and will be accessible through the company's Investor Relations website. A replay will be available until November 7, 2025.
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Nick Colangelo, along with CFO Joe Mara, will engage in a fireside chat on Friday, September 6, 2024, at 1:05 p.m. ET.
This presentation offers investors and interested parties an opportunity to gain insights into Vericel's operations, strategies, and market position. The event will be accessible via webcast on the Investor Relations section of Vericel's website, allowing for widespread viewing and potential increased investor engagement.
Vericel (NASDAQ:VCEL) has announced FDA approval for MACI Arthro, the first restorative biologic cartilage repair product approved for arthroscopic administration. This expansion of the MACI® label allows for less invasive repair of knee cartilage defects up to 4 cm2. MACI Arthro targets the largest segment of MACI's $3 billion addressable market, focusing on 2-4cm2 defects on femoral condyles, representing about 20,000 patients annually. The company is expanding its target surgeon base from 5,000 to 7,000 to include those performing high volumes of arthroscopic cartilage repair surgeries. This approval is expected to support sustained top-tier revenue growth for Vericel in the coming years.
